[go: up one dir, main page]

PE20130191A1 - Combinaciones que contienen 2, 3-dihidroimidazo[1, 2-c]quinazolina sustituida - Google Patents

Combinaciones que contienen 2, 3-dihidroimidazo[1, 2-c]quinazolina sustituida

Info

Publication number
PE20130191A1
PE20130191A1 PE2012002028A PE2012002028A PE20130191A1 PE 20130191 A1 PE20130191 A1 PE 20130191A1 PE 2012002028 A PE2012002028 A PE 2012002028A PE 2012002028 A PE2012002028 A PE 2012002028A PE 20130191 A1 PE20130191 A1 PE 20130191A1
Authority
PE
Peru
Prior art keywords
dihydroimidazo
quinazoline
halogen
substitute
combinations containing
Prior art date
Application number
PE2012002028A
Other languages
English (en)
Inventor
Ningshu Liu
Andrea Hagerbarth
Katja Haike
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44144895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130191(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of PE20130191A1 publication Critical patent/PE20130191A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMBINACION DE: I) UNO O MAS COMPUESTOS 2,3-DIHIDROIMIDAZO[1,2-C]QUINAZOLINA DE FORMULA (A1) DONDE: X ES NH O CR5R6; Y1 ES CR3 O N; EL ENLACE Y2----Y3 ES UNA UNION SIMPLE O DOBLE; Z1, Z2, Z3 Y Z4 SON INDEPENDIENTEMENTE CH, CR2 O N; R1 ES ARILO OPCIONALMENTE CON 1 A 3 SUSTITUYENTES, ENTRE OTROS; R3 ES H, HALOGENO, ENTRE OTROS; R5 ES H O ALQUILO C1-C6; R6 ES HALOGENO, H, ENTRE OTROS; II) UNO O MAS COMPUESTOS N-(2-ARILAMINO)ARILSULFONAMIDA DE FORMULA (B), DONDE G ES METILO OPCIONALMENTE SUSTITUIDO, ENTRE OTROS; Rº ES H, HALOGENO, ENTRE OTROS; X ES F, Cl O METILO; Y ES I, Br, Cl, ENTRE OTROS; Z ES H O F; Y III) UNO O MAS AGENTES FARMACEUTICO ADICIONALES. DICHA COMBINACION ES UTIL PARA EL TRATAMIENTO DE CANCER PANCREATICO, CARCINOMA DE HEPATOCITOS, CANCER DE MAMA
PE2012002028A 2010-04-16 2011-04-14 Combinaciones que contienen 2, 3-dihidroimidazo[1, 2-c]quinazolina sustituida PE20130191A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10160109 2010-04-16

Publications (1)

Publication Number Publication Date
PE20130191A1 true PE20130191A1 (es) 2013-02-21

Family

ID=44144895

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012002028A PE20130191A1 (es) 2010-04-16 2011-04-14 Combinaciones que contienen 2, 3-dihidroimidazo[1, 2-c]quinazolina sustituida

Country Status (24)

Country Link
US (1) US20130184270A1 (es)
EP (1) EP2558126A2 (es)
JP (1) JP5886271B2 (es)
KR (1) KR20130098155A (es)
CN (1) CN102958540B (es)
AU (1) AU2011240003A1 (es)
BR (1) BR112012026480A2 (es)
CA (1) CA2796253A1 (es)
CL (1) CL2012002887A1 (es)
CO (1) CO6620036A2 (es)
CR (1) CR20120524A (es)
CU (1) CU20120150A7 (es)
DO (1) DOP2012000269A (es)
EA (1) EA201201414A8 (es)
EC (1) ECSP12012261A (es)
IL (1) IL222356A0 (es)
MA (1) MA34158B1 (es)
MX (1) MX2012012064A (es)
PE (1) PE20130191A1 (es)
PH (1) PH12012502069A1 (es)
SG (1) SG184550A1 (es)
TN (1) TN2012000493A1 (es)
WO (1) WO2011128407A2 (es)
ZA (1) ZA201208616B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
WO2014160034A1 (en) * 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Aldehyde dehydrogenase-1 modulators and methods of use thereof
EP2983669B1 (en) 2013-04-08 2018-10-24 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
WO2015082376A2 (en) * 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
TN2017000385A1 (en) * 2015-03-09 2019-01-16 Bayer Healthcare Pharmaceuticals Inc Use of substituted 2,3-dihydroimidaz0[1,2-c]quinazolines.
JP6867295B2 (ja) 2015-03-09 2021-04-28 バイエル ファーマ アクチエンゲゼルシャフト 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンを含んでいる組合せ
US10844066B2 (en) 2016-03-08 2020-11-24 Bayer Pharma Aktiengesellschaft 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides
US11185549B2 (en) 2017-06-28 2021-11-30 Bayer Consumer Care Ag Combination of a PI3K-inhibitor with an androgen receptor antagonist
EP3723754A4 (en) * 2017-12-13 2021-05-19 Merck Sharp & Dohme Corp. IMIDAZO [1,2-C] QUINAZOLINE-5-AMINE COMPOUNDS WITH PROPERTIES OF A2A ANTAGONIST

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
HRP20050375B1 (hr) * 2002-09-30 2014-03-14 Bayer Intellectual Property Gmbh Taljeni azol-pirimidin derivati
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
DE102004037875B4 (de) 2004-08-04 2008-05-08 Siemens Ag Sensorvorrichtung, Verfahren und Vorrichtung zum Überwachen einer Sensorvorrichtung
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
MX2008002114A (es) * 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EA201001639A1 (ru) * 2008-04-14 2011-06-30 Арди Байосайенсиз, Инк. Композиции и способы их получения и применения
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma

Also Published As

Publication number Publication date
DOP2012000269A (es) 2012-12-15
ZA201208616B (en) 2015-08-26
HK1182937A1 (en) 2013-12-13
TN2012000493A1 (en) 2014-04-01
WO2011128407A9 (en) 2011-12-22
EP2558126A2 (en) 2013-02-20
SG184550A1 (en) 2012-11-29
CO6620036A2 (es) 2013-02-15
WO2011128407A3 (en) 2012-02-23
IL222356A0 (en) 2012-12-31
BR112012026480A2 (pt) 2016-08-16
CR20120524A (es) 2013-01-09
US20130184270A1 (en) 2013-07-18
CN102958540B (zh) 2015-09-02
MX2012012064A (es) 2012-12-17
JP2013525293A (ja) 2013-06-20
PH12012502069A1 (en) 2013-02-04
MA34158B1 (fr) 2013-04-03
KR20130098155A (ko) 2013-09-04
WO2011128407A2 (en) 2011-10-20
EA201201414A1 (ru) 2013-04-30
EA201201414A8 (ru) 2013-12-30
JP5886271B2 (ja) 2016-03-16
CU20120150A7 (es) 2013-02-26
CL2012002887A1 (es) 2013-01-18
ECSP12012261A (es) 2012-11-30
AU2011240003A1 (en) 2012-11-08
CA2796253A1 (en) 2011-10-20
CN102958540A (zh) 2013-03-06

Similar Documents

Publication Publication Date Title
PE20130191A1 (es) Combinaciones que contienen 2, 3-dihidroimidazo[1, 2-c]quinazolina sustituida
PE20180462A1 (es) Moduladores cot y metodos de uso de los mismos
MX384948B (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos.
CU20120101A7 (es) Derivados de triazolopirazinas sustituidas como inhibidores del receptor c-met o hgf para tratar el cáncer
NI200900040A (es) Derivados de quinazolinona 5-substituidos como agentes antitumorales.
BR112014027143A2 (pt) pirrolobenzodiazepinas
EA200971081A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
PE20091561A1 (es) Compuestos inhibidores de raf y metodos para su uso
CY1119499T1 (el) Ενωσεις 6,7-διυδροπυραζολο[1,5-α]πυραζιν-4(5η)-ονης και η χρηση τους ως αρνητικοι αλλοστερικοι τροποποιητες των υποδοχεων mglur2
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
PE20150684A1 (es) Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr)
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
EA202090860A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
MX379579B (es) Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para su uso.
EA201171062A1 (ru) Алкиламидные соединения и их применение
UY30748A1 (es) Compuesto0s novedosos
GT200800158A (es) Pirazolquinolonas como potentes inhibidores de parp
EA201491607A1 (ru) Модуляторы толлподобных рецепторов
MX2019012467A (es) Conjugados de pirrolobenzodiazepina.
DOP2011000076A (es) Derivados de heteroaril amidas y su uso como activadores de glucoquinasa
EA201071234A1 (ru) Производные изохинолинона в качестве nk3 антагонистов
CL2012001072A1 (es) Compuestos derivados de feniletinilo, moduladores alostericos positivos del receptor de glutamato (mglur5); procedimiento de preparacion; composicion farmaceutica; y uso para tratar esquizofrenia o enfermedades cognitivas.
CR11098A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer

Legal Events

Date Code Title Description
FD Application declared void or lapsed